Researchers conduct population level observational study of the SARS-CoV-2 Alpha variant

In 2021, several new variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged and spread throughout the world. Some of these new variants include the Alpha, Beta, Gamma, Delta, Lambda, and Eta strains.

Study: SARS-CoV-2 alpha variant: is it really more deadly? A population level observational study. Image Credit: Corona Borealis Studio / Shutterstock.com

*Important notice: medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

The rapid spread of the Alpha variant

While the SARS-CoV-2 Alpha variant was first detected in the United Kingdom, it quickly spread to other countries around world. In fact, by mid-January 2021, the Alpha variant was detected in twelve states in the United States of America. Simultaneously, this variant had also become the dominant circulating strain in Israel, where it accounted for more than 90% of new cases.

Upon detection of the Alpha variant in Israel, the country intensified its surveillance as well as prioritized rapid vaccination. Although the Alpha variant strain was reported to be more transmissible than the original SARS-CoV-2 strain, there have been conflicting reports on whether this variant is also deadlier than the wild type strain.

To this end, in a recent study published on the pre-print server medRxiv,* researchers analyzed the coronavirus disease 2019 (COVID-19) data obtained from Israel to determine whether the Alpha variant led to a higher fatality rate.

How was the study carried out?

In the current study, the researchers analyzed data published by the Israel Ministry of Health from March 1, 2020, to February 28, 2021.

Calculation of crude mortality rate was done by summing the deaths divided by the total population of Israel. Additionally, case-fatality rates were calculated weekly to minimize all weekend under-reporting biases.

What did the study find?

Case-fatality rates in Israel quickly rose during the start of the pandemic and peaked in May 2020.

On December 22, 2020, the Alpha variant was first detected in Israel. By January 2021, the Alpha variant quickly became the dominant circulating strain throughout this nation.

Despite the increasing dominance of the Alpha variant in 2021, case fatality rates were not found to rise. In fact, cumulative case-fatality rates were found to decrease from 1.25% in July 2020 to 0.74% at the end of March 2021.

Weekly case fatality and overall mortality rates in Israel.

Taken together, the emergence of the Alpha variant was associated with higher crude mortality rates and lower case fatality rates. The authors speculate that the changes in these rates are likely due to the more infectious but less deadly nature of the Alpha strain.

Cumulative case fatality rates from November 2020 until the end of January 2021. The horizontal yellow line marks the date the alpha variant first appeared in Israel. Variant proportions are illustrated.

“A possible explanation of our findings is that Alpha variant infected more people over time in Israel and the U.K., but once infected, these people were no more likely to die than people infected with the wild-type virus.”

Publicly available data from many countries also showed that fatality rates did not rise above December 2020 levels, despite the rapid spread of the Alpha variant. In fact, fatality rates in Israel were found to be lower than those in the U.K. due to the presence of a much younger population.

In conclusion, the researchers stated that although the Alpha variant is more transmissible, it does not appear to be more deadly than the ancestral SARS-CoV-2 variant.

*Important notice: medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Journal reference:
Suchandrima Bhowmik

Written by

Suchandrima Bhowmik

Suchandrima has a Bachelor of Science (B.Sc.) degree in Microbiology and a Master of Science (M.Sc.) degree in Microbiology from the University of Calcutta, India. The study of health and diseases was always very important to her. In addition to Microbiology, she also gained extensive knowledge in Biochemistry, Immunology, Medical Microbiology, Metabolism, and Biotechnology as part of her master's degree.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Bhowmik, Suchandrima. (2021, August 24). Researchers conduct population level observational study of the SARS-CoV-2 Alpha variant. News-Medical. Retrieved on October 06, 2024 from https://www.news-medical.net/news/20210824/Researchers-conduct-population-level-observational-study-of-the-SARS-CoV-2-Alpha-variant.aspx.

  • MLA

    Bhowmik, Suchandrima. "Researchers conduct population level observational study of the SARS-CoV-2 Alpha variant". News-Medical. 06 October 2024. <https://www.news-medical.net/news/20210824/Researchers-conduct-population-level-observational-study-of-the-SARS-CoV-2-Alpha-variant.aspx>.

  • Chicago

    Bhowmik, Suchandrima. "Researchers conduct population level observational study of the SARS-CoV-2 Alpha variant". News-Medical. https://www.news-medical.net/news/20210824/Researchers-conduct-population-level-observational-study-of-the-SARS-CoV-2-Alpha-variant.aspx. (accessed October 06, 2024).

  • Harvard

    Bhowmik, Suchandrima. 2021. Researchers conduct population level observational study of the SARS-CoV-2 Alpha variant. News-Medical, viewed 06 October 2024, https://www.news-medical.net/news/20210824/Researchers-conduct-population-level-observational-study-of-the-SARS-CoV-2-Alpha-variant.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Long COVID affects 38% of emergency patients with persistent symptoms